Estimasi Presentase Attributable Risk Pada Populasi (PAR%) Dan Fraksi Etiologis (EF) Faktor Risiko MDR-TB Di RSUD Kota Makassar
DOI:
https://doi.org/10.33096/mwcbd048Keywords:
MDR-TB, Population Attributable Risk, Etiologic Fraction, anti-tuberculosis drus side effectsAbstract
Tuberculosis (TB) remains a global health problem with 10.7 million new cases and 1.23 million deaths in 2024, further compounded by the emergence of multidrug-resistant tuberculosis (MDR-TB). Existing analyses of MDR-TB risk factors remain limited to the Odds Ratio (OR), which is unable to quantify the magnitude of risk factor contributions at the population level. This study aimed to estimate the Population Attributable Risk Percent (PAR%) and Etiologic Fraction (EF) of risk factors for MDR-TB incidence at Makassar City Regional General Hospital (RSUD Kota Makassar) in 2024. This study is a secondary data analysis based on a publication by Janna et al. (2025), with a sample of 111 TB patients (37 MDR-TB cases and 74 non-MDR-TB controls). PAR% was calculated using Levin's formula [Pₑ(OR−1) / Pₑ(OR−1)+1] × 100% and EF using the formula [(OR−1)/OR] × 100%, focusing on variables that were statistically significant (p < 0.05) with OR > 1. Of the seven variables analyzed, three were statistically significant, namely, side effects of anti-tuberculosis drugs (ATD) with PAR% 93.8% and EF 97.6%; history of previous TB treatment with PAR% 66.3% and EF 90.1%; and undernutritional status (BMI < 18.5 kg/m²) with PAR% 38.2% and EF 61.5%. Management of ATD side effects represents the primary intervention priority, with the potential to prevent 93.8% of MDR-TB cases at RSUD Kota Makassar.
References
1. World Health Organization. Global tuberculosis report 2025. Geneva: WHO; 2025. Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2025
2. Goletti D, Meintjes G, Andrade BB, Zumla A, Lee SS. Insights from the 2024 WHO global tuberculosis report: more comprehensive action, innovation, and investments are required for achieving WHO End TB goals. Int J Infect Dis. 2025;150:107325. doi:10.1016/j.ijid.2024.107325
3. Xi Y, Zhang W, Qiao RJ, Tang J. Risk factors for multidrug-resistant tuberculosis: a worldwide systematic review and meta-analysis. PLoS ONE. 2022;17(6):e027000 3. doi:10.1371/journal.pone.0270003
4. Alene KA, Wangdi K, Clements ACA. Impact of the COVID-19 pandemic on tuberculosis control: An overview. 2020;5(3):123. doi:10.3390/tropicalmed5030123
5. Lestari BW, Nijman G, Larasmanah A, Soeroto AY, Santoso P, Alisjahbana B, et al. Management of drug-resistant tuberculosis in Indonesia: a four-year cascade of care analysis. Lancet Reg Health Southeast Asia. 2024;22:100294. doi:10.1016/j.lansea.2023.100294
6. Sugiyono RI, Naysilla AM, Susanto NH, Handayani D, Burhan E, Karuniawati A, et al. Treatment outcomes of pulmonary TB in adults in Indonesia. IJTLD Open. 2025;2(3):145-152. doi:10.5588/ijtldopen.24.0482.
7. Majid R, Zainuddin A, Sabilu Y, Irma I, Nurjannah N. Factors related to sufferer behavior in preventing tuberculosis transmission in the family. Window of Health: Jurnal Kesehatan. 2023;6(4):443–454. doi:10.33096/woh.vi.400
8. Nindrea RD, Ming LC, Agustian DR. Family support, motivation, and patient adherence to tuberculosis treatment: insights from Indonesia. Afr J Infect Dis. 2025;19(2):5. doi:10.21010/Ajidv19i2.5
9. Nindrea RD, Susanti R, Indika PM, Maisa BA, Sukma M, Rosalina L, et al. Modifiable and non-modifiable risk factors for tuberculosis among adults in Indonesia: a systematic review and meta-analysis. Afr J Infect Dis. 2024;18(2):19–28. doi:10.21010/Ajidv18i2.3
10. Janna TAS, Arsin AA, Arsyad DS, Arsyad M. Analisis faktor risiko kejadian multidrug-resistant tuberculosis (MDR-TB) di RSUD Kota Makassar. Jurnal Mitrasehat. 2025;15(2):899–912. doi:10.51171/jms.v15i2.533
11. Hardianti A, Fitri AU, Atiqa UD. Tren penyakit tertinggi berdasarkan laporan surveilans terpadu 2021-2023 di Provinsi Sulawesi Selatan. J Promot Prev. 2025;8(2):229-236. doi:10.47650/jpp.v8i2.1734.
12. Rismayanti, Nyomba MA, Ansariadi A, Devana AT. Analisis determinan tuberculosis di Kota Makassar. Media Publikasi Promosi Kesehatan Indonesia (MPPKI). 2023;6(2):290–295. doi:10.56338/mppki.v6i2.3038.
13. Islam F, Ahmad H, Nurbaya, Ahmad M, Ansar, Ramadhan K, et al. Factors affecting treatment adherence among patients with tuberculosis in Indonesia: literature review. J Public Health Pharm. 2024;4(1):28–37. doi:10.56338/jphp.v4i1.5022.
14. Hasbi AMFZ, Gobel FA, Sulaeman U. Distribusi spasial faktor determinan kejadian tuberkulosis paru di wilayah kerja Puskesmas Kassi-Kassi Kota Makassar. Window Public Health J. 2023;4(3):417-427. doi:10.33096/woph.v4i3.790.
15. Ferris LE. A dictionary of epidemiology. CMAJ. 1995;153(12):1753-1754.
16. Brooks-Pollock E, Danon L. Defining the population attributable fraction for infectious diseases. Int J Epidemiol. 2017;46(3):976–982. doi:10.1093/ije/dyx055
17. Bhargava A, Bhargava M, Beneditti A, Kurpad A. Attributable is preventable: corrected and revised estimates of population attributable fraction of TB related to undernutrition in 30 high TB burden countries. J Clin Tuberc Other Mycobact Dis. 2022;27:100309. doi:10.1016/j.jctube.2022.100309
18. Yunilistianingsih Y, Ambariyah N, Ningrum VDA. Short-term treatment of multidrug-resistant tuberculosis: a multicenter study of therapeutic effectiveness and adverse drug reactions in Yogyakarta, Indonesia. Pan Afr Med J. 2025;52:62. doi:10.11604/pamj.2025.52.62.45831.
19. Soedarsono S, Mertaniasih NM, Kusmiati T, Permatasari A, Ilahi WK, Anggraeni AT. Characteristics of previous tuberculosis treatment history in patients with treatment failure and the impact on acquired drug-resistant tuberculosis. Antibiotics. 2023;12(3):598. doi:10.3390/antibiotics12030598
20. Franco JVA, Bongaerts B, Metzendorf MI, Risso A, Guo Y, Peña Silva L, et al. Undernutrition as a risk factor for tuberculosis disease. Cochrane Database Syst Rev. 2024;6:CD015890. doi:10.1002/14651858.CD015890.pub2
21. World Health Organization. Tuberculosis and malnutrition. Geneva: WHO; 2022. Available from: https://www.who.int/docs/librariesprovider2/default-document-library/booklet_200424.pdf
22. Porta M, editor. A Dictionary of Epidemiology. 6th ed. Oxford: Oxford University Press; 2014. doi:10.1093/acref/9780199976720.001.0001
23. Sadeghi K, Poorolajal J, Doosti-Irani A. Prevalence of modifiable risk factors of tuberculosis and their population attributable fraction in Iran: a cross-sectional study. PLoS ONE. 2022;17(8):e0271511. doi:10.1371/journal.pone.0271511
24. Indriyati LH, Eitoku M, Naw Awn JP, Nishimori M, Hamada N, Sawitri N, et al. Influences of radiographic silicosis and drug supervisors on the development of multidrug-resistant tuberculosis in West Java, Indonesia. Environ Health Prev Med. 2025;30:17. doi: 10.1265/ehpm. 24-00169
25. Ferguson J, O'Leary N, Maturo S, Gaughan D. Bias assessment and correction for Levin's population attributable fraction in the presence of confounding. Am J Epidemiol. 2024;193(3):1. doi:10.1093/aje/kwad222
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Alief Ihram Fatany, Andi Nursiah, Idris
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
